IGM Biosciences, Inc.
IGMSDelisted Aug 14, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001496323
IGM Biosciences, Inc. was delisted on Aug 14, 2025; its insiders filed their last Form 4 on Aug 18, 2025; 66 institutions reported holding it in 13F filings for Q2 2025, worth $17.9M in total; no superinvestor held it.
13F holders, Q2 2021
Institutional positions in IGM Biosciences, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- −4 vs. Q1 2021
- Shares held
- 16.3M
- −1.66M (−9.2%) vs. Q1 2021
- Total value
- $1.36B
- −$22.1M (−1.6%) vs. Q1 2021
- New holders
- 18
- 38 more added
- Sold out
- 22
- 32 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IGMS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 1 | $508 |
| Q2 2025 | 66 | $17.9M |
| Q1 2025 | 79 | $20.5M |
| Q4 2024 | 85 | $132.8M |
| Q3 2024 | 72 | $356.6M |
| Q2 2024 | 82 | $152.9M |
| Q1 2024 | 87 | $220.3M |
| Q4 2023 | 72 | $182.1M |
| Q3 2023 | 79 | $186.3M |
| Q2 2023 | 79 | $207.6M |
| Q1 2023 | 75 | $245.4M |
| Q4 2022 | 82 | $305.8M |
| Q3 2022 | 93 | $402.0M |
| Q2 2022 | 89 | $315.6M |
| Q1 2022 | 93 | $487.4M |
| Q4 2021 | 87 | $517.3M |
| Q3 2021 | 107 | $1.11B |
| Q2 2021 | 105 | $1.36B |
| Q1 2021 | 109 | $1.38B |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding IGM Biosciences, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Alkeon Capital Management LLC | 1,051,429 | $87.5M | 0.31% | −2,123−0.2% | Reduced |
| Artal Group S.A. | 1,100,000 | $91.5M | 2.08% | −25,000−2.2% | Reduced |
| Price T Rowe Associates Inc | 1,986,071 | $165.2M | 0.02% | +189,760+10.6% | Added |
| Baker Bros. Advisors LP | 3,156,102 | $262.6M | 1.15% | 00.0% | Unchanged |
| Redmile Group, LLC | 3,425,455 | $285.0M | 4.22% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 0 | $0 | 0.00% | −982,723−100.0% | Sold out |
| Avidity Partners Management LP | 0 | $0 | 0.00% | −293,000−100.0% | Sold out |
| Janus Henderson Group PLC | 0 | $0 | 0.00% | −268,933−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −47,514−100.0% | Sold out |
| Marshall Wace North America L.P. | 0 | $0 | 0.00% | −39,090−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −26,046−100.0% | Sold out |
| Vivo Capital, LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −18,921−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −15,624−100.0% | Sold out |
| California Public Employees Retirement System | 0 | $0 | 0.00% | −14,400−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −7,025−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −5,284−100.0% | Sold out |
| Essex Investment Management Co LLC | 0 | $0 | 0.00% | −4,073−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −3,902−100.0% | Sold out |
| Athanor Capital, LP | 0 | $0 | 0.00% | −3,234−100.0% | Sold out |
| L & S Advisors Inc | 0 | $0 | 0.00% | −3,000−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −2,875−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −890−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −217−100.0% | Sold out |
| International Assets Investment Management, LLC | 0 | $0 | 0.00% | −175−100.0% | Sold out |
| Grandview Asset Management LLC | 0 | $0 | 0.00% | −61−100.0% | Sold out |